Ken Griffin Annovis Bio, Inc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 109,200 shares of ANVS stock, worth $252,252. This represents 0.0% of its overall portfolio holdings.
Number of Shares
109,200
Previous 33,000
230.91%
Holding current value
$252,252
Previous $71,000
215.49%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ANVS
# of Institutions
49Shares Held
2.03MCall Options Held
167KPut Options Held
97.2K-
Vanguard Group Inc Valley Forge, PA738KShares$1.7 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA218KShares$504,5520.0% of portfolio
-
Geode Capital Management, LLC Boston, MA184KShares$425,3950.0% of portfolio
-
Northern Trust Corp Chicago, IL121KShares$279,6480.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$232,6370.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $18.9M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...